Psychedelic Psychotherapy Clinics
Are Psychedelic Psychotherapy Clinics the Future?
Psychedelic treatments are a rising trend in the psychotherapy realm with patients seeking out clinics that offer psilocybin doses as medication. In various parts of the world, psychedelic psychotherapy clinics are providing a new hope to patients with treatment resistant mental health issues, anxiety, PTSD and depression1https://www.sciencedirect.com/science/article/pii/S2215036616300657. Not only are more clinics adding psychedelics to the menu of treatments but additional training is being offered on how to administer doses to patients.
Over the last decade, Western medicine has begun to seek alternative forms of medication. The addictive nature of opioids has led many in the medical community to seek out something less addiction forming and a better working medication. Psychedelics are fast emerging as the answer with many institutions and companies committing significant funding to the research and development of Psychedelic Psychotherapy.
John Hoskins University in particular has been leading the psychedelic medical renaissance with studies into the effectiveness of psilocybin for opioid addiction, Alzheimer’s, PTSD, post-treatment Lyme disease syndrome, eating disorders and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients.
Psilocybin isn’t the only psychedelic that clinics are offering patients. Some luxury wellness centers have other mind-expanding drugs on their menus including ketamine, ibogaine, and ayahuasca. All three are drugs are still seen as having no medical use when taken recreationally yet, in medical settings, all three have shown the potential to alter the life of a person suffering from a mental health disorder in a positive way.
Psychedelic psychotherapy clinics deliver medication in small doses often twice week for a set amount of time. Doses are followed by psychotherapy sessions. Both doses and psychotherapy sessions are conducted in a clinic and overseen by a psychotherapists and medical staff.
Psychedelic Psychotherapy Clinics
Because of the nature of evolving laws and research developments there is still confusion among patients as to the legality to various treatments. Psychedelic psychotherapy clinics are not routinely available in every country, even though there is predicted to be an overwhelming explosion of these specialist clinics over the next decade.
Physis Recovery™ is the leading Psychedelic Psychotherapy Clinic in the World and currently facilitates its own luxury Tripnotherapy™ Clinics regularly in Portugal, Netherlands, Brazil and Antigua.
No Tripnotherapy™ clinics are currently offered from Physis luxury locations in Asia.
MDMA Assisted Therapy
Much research has been done into the positive effects of MDMA on Post Traumatic Stress Disorder. Medication with MDMA has been shown to reduce blood flow to the amygdala, while increasing blood flow to the occipital cortex and ventromedial prefrontal cortex.2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122379/
MDMA has been clinically proven to state reduce fear and amplify consciousness.3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917000/ MDMA increases levels of mood regulating serotonin, oxytocin, prolactin, and cortisol. Key to the effectiveness of MDMA assisted therapy is the release of oxytocin, which of course increases trust and emotional awareness and reduces the amygdala ‘fight or flight’ response.
Research has shown these effects foster memory reconsolidation by allowing the patient to access the traumatic memory while feeling detached from the sense of imminent threat.
Psychedelic Psychotherapy Clinics
In spite of psychedelic drugs being illegal in most countries, the medical setting in which the doses are administered by a trained professional, changes the context of the experience. In the same way that opioids given in a medical setting are safe, the consumption of psychedelics can be too. Medical monitoring is conducted throughout the psychedelic session.
While an individual who takes psilocybin in a party setting can experience a psychedelic trip, patients given low doses will simply feel a slight intoxication. This enables them to have a personal experience they later reflect on in a psychotherapy session that provides healing.
One of the interesting aspects of psychedelic psychotherapy clinics is the investment currently being funneled into them. It is this investment and the potential for investors to make large sums of profit that could make clinics offering the therapy commonplace. Where there is the potential for individuals and businesses to make money, there is the chance for once criminalized plant based and naturally occurring medicine to receive FDA approval.4https://maps.org/about
The next decade should see a greater rise in psychedelic psychotherapy clinics. Medical centers are now better organized and run better than in the past. Research is being increased and investors are coming on board.
By 2030, there are likely to be thousands of psychedelic psychotherapy clinics with jobs available for nearly a quarter of a million medical personnel. Not only will the clinics provide help to hundreds of thousands of people.
Like medical marijuana, psychedelics are likely to see new legislation in multiple countries approve its use in clinics with trained professionals overseeing the use. With the rise in clinics, the chances that more people with mental health issues to receive much needed help is likely to improve.
1. A Hofmann, A Frey, H Ott, T Petr Zilka, F TroxlerElucidation of the structure and the synthesis of psilocybin Experientia, 14 (1958), pp. 397-399 Google Scholar
3. American Psychiatry Association . Diagnostic and statistical manual of mental disorders. 5. Arlington, VA: American Psychiatric Publishing; 2013. [Google Scholar]
4. Bedi G, Phan KL, Angstadt M, de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) 2009;207(1):73–83. doi: 10.1007/s00213-009-1635-z. [PMC free article] [PubMed] [Google Scholar]
5. Bouso JC, Doblin R, Farré M, Alcázar M, Gómez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs. 2008;40(3):225–236. doi: 10.1080/02791072.2008.10400637. [PubMed] [Google Scholar]
6. Doukas A, D’Andrea W, Doran J, et al. Psychophysiological predictors of working alliance among treatment-seeking women with complex trauma exposure. Journal of Traumatic Stress. 2014;27:672–679. doi: 10.1002/jts.21968. [PubMed] [Google Scholar]
7. Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD) Journal of Psychopharmacology. 2013;27(1):40–52. doi: 10.1177/0269881112464827. [PubMed] [Google Scholar]
8. Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. Journal of Psychopharmacology. 2006;20:400–410. doi: 10.1177/0269881106061514. [PubMed] [Google Scholar]